Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons
Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons
复制标题
DOI：
10.1097/adm.0000000000000718
复制
发表时间：
2020-09-01
影响因子：
5.5
通讯作者：
Saloner, Brendan
中科院分区：
文献类型：
--
作者：
Bandara, Sachini;Kennedy-Hendricks, Alene;Saloner, Brendan
目的：描述新型冠状病毒(新冠肺炎)大流行如何影响监狱中的阿片激动剂治疗(OAT)计划。方法：2020年5月，我们对19个在新冠肺炎之前为服刑人群提供美沙酮和/或丁丙诺啡治疗的医疗系统进行了在线调查。11个调查项目检查了大流行给这些方案带来的挑战和变化。19个节目中有16个(84%)回答了调查。结果：16个系统中有10个报告缩减了OAT计划。16个系统中有7个对药物分配流程进行了更改。一半的系统报告了实施物理距离(n=8)和/或获得个人防护装备(n=8)的挑战。在16个系统中，有13个系统由于新冠肺炎感染风险，部分燕麦片计划参与者提前出院。结论：在新冠肺炎大流行的背景下，拥有现有燕麦片方案的监狱和监狱已经缩减了它们的业务。鉴于围绕燕麦片治疗阿片类药物使用障碍和避免过量死亡的强有力的证据基础，在监禁设施努力实施新冠肺炎缓解措施之际，需要在保持和增加用药渠道方面提供指导。
Objectives: To describe how the novel coronavirus (COVID-19) pandemic has affected opioid agonist treatment (OAT) programs in jails and prisons. Methods: In May 2020, we conducted an online survey of 19 carceral systems that provided methadone and/or buprenorphine treatment for incarcerated populations before COVID-19. Eleven survey items examined challenges and changes to these programs as a result of the pandemic. Sixteen of 19 programs (84%) responded to the survey. Results: Ten out of 16 systems reported downsizing their OAT programs. Seven of 16 systems made changes to medication dispensation processes. Half of systems report challenges implementing physical distancing (n = 8), and/or obtaining personal protective equipment (n = 8). In 13 out of 16 systems some OAT program participants were released early due to COVID-19 infection risk. Conclusions: Jails and prisons with existing OAT programs have curtailed their operations in the context of the COVID-19 pandemic. Given the robust evidence base around OAT for treating opioid use disorder and averting overdose deaths, guidance is needed on maintaining and ramping up medication access as carceral facilities grapple with implementing COVID-19 mitigation.